SGLT-2 diabetes drug Jardiance outsells mkt leader Forxiga
By Nho, Byung Chul | translator Kang, Shin-Kook
24.06.26 05:59:52
가나다라
0
Boehringer Ingelheim’s Jardiance, 1Q Revenue KRW 11.1 billion...AstraZeneca’s Forxiga, 8.0 billion
Forxiga’s sales remain strong despite rumors of market withdrawal of the single-agent product
Jardiance seeks reimbursement extension to cover kidney disease following diabetes and heart failure
Boehringer Ingelheim's Jardiance and AstraZeneca's Forxiga are striving for mastery of the KRW 110 billion SGLT-2 inhibitor class single-agent diabetes drug market in Korea.
In the first quarter of this year, Jardiance and Forxiga generated sales in the range of KRW 11.1 billion and KRW 8.0 billion, respectively. Notably, this is a reversal of fortune for Forxiga, which had held the lead SGLT-2 class drug market for the past 5 years.
In 2020-2021-2022-2023, Forxiga was ahead of second-place Jardiance with sales of KRW 32.2 billion, KRW 38.1 billion, KRW 45.4 billion, and KRW 49.9 billion, but in the first quarter of this year, Jardiance outperformed Forxiga by nearly KRW 3 billio
Nho, Byung Chul(sasiman@dailypharm.com)
If you want to see the full article, please JOIN US (click)